Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Blier

Showing results (221-230 of 229) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 229 results.
Clinical Pharmacology and Therapeutics|January 22, 2023
ABCB1 Gene Variants and Antidepressant Treatment Outcomes: A Systematic Review and Meta-Analysis Including Results from the CAN-BIND-1 StudyLeen Magarbeh, Claudia Hassel, Maximilian Choi, et al.
The Journal of Clinical Psychiatry|March 7, 2019
Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 ReportSidney H Kennedy, Raymond W Lam, Susan Rotzinger, et al.
Molecular Psychiatry|September 7, 2022
International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderatorsRebecca B Price, Nicholas Kissel, Andrew Baumeister, et al.
Frontiers in Psychiatry|February 24, 2022
Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain DisordersAnthony L Vaccarino, Derek Beaton, Sandra E Black, et al.
Nature Communications|May 23, 2017
MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genesJuan Pablo Lopez, Laura M Fiori, Cristiana Cruceanu, et al.
BMC Psychiatry|April 17, 2016
Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohortRaymond W Lam, Roumen Milev, Susan Rotzinger, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|May 7, 2024
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultesRaymond W Lam, Sidney H Kennedy, Camelia Adams, et al.
CNS Spectrums|July 15, 2022
The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depressionVincent Van den Eynde, Wegdan R Abdelmoemin, Magid M Abraham, et al.
Molecular Psychiatry|December 15, 2021
A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trialsLuca Sforzini, Courtney Worrell, Melisa Kose, et al.
Pageof 23

Showing results (221-230 of 229) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 229 results.
Clinical Pharmacology and Therapeutics|January 22, 2023
ABCB1 Gene Variants and Antidepressant Treatment Outcomes: A Systematic Review and Meta-Analysis Including Results from the CAN-BIND-1 StudyLeen Magarbeh, Claudia Hassel, Maximilian Choi, et al.
The Journal of Clinical Psychiatry|March 7, 2019
Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 ReportSidney H Kennedy, Raymond W Lam, Susan Rotzinger, et al.
Molecular Psychiatry|September 7, 2022
International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderatorsRebecca B Price, Nicholas Kissel, Andrew Baumeister, et al.
Frontiers in Psychiatry|February 24, 2022
Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain DisordersAnthony L Vaccarino, Derek Beaton, Sandra E Black, et al.
Nature Communications|May 23, 2017
MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genesJuan Pablo Lopez, Laura M Fiori, Cristiana Cruceanu, et al.
BMC Psychiatry|April 17, 2016
Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohortRaymond W Lam, Roumen Milev, Susan Rotzinger, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|May 7, 2024
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultesRaymond W Lam, Sidney H Kennedy, Camelia Adams, et al.
CNS Spectrums|July 15, 2022
The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depressionVincent Van den Eynde, Wegdan R Abdelmoemin, Magid M Abraham, et al.
Molecular Psychiatry|December 15, 2021
A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trialsLuca Sforzini, Courtney Worrell, Melisa Kose, et al.
Pageof 23